These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 9616891)
21. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen. Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060 [TBL] [Abstract][Full Text] [Related]
22. The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate? Reiter W; Stieber P; Schmeller N; Nagel D; Jansen HM; Schambeck C; Fabricius PG; Pahl H; Mattes M; Constabel H; Fateh-Moghadam A Anticancer Res; 1997; 17(4B):2987-91. PubMed ID: 9329582 [TBL] [Abstract][Full Text] [Related]
23. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men. Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M Urol J; 2009; 6(3):182-8. PubMed ID: 19711272 [TBL] [Abstract][Full Text] [Related]
24. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. Chung BH; Hong SJ; Cho JS; Seong DH BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765 [TBL] [Abstract][Full Text] [Related]
25. [Value of prostate specific antigen in early diagnosis of prostatic cancer]. Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162 [TBL] [Abstract][Full Text] [Related]
26. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men. Akduman B; Alkibay T; Tuncel A; Bozkirli I Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873 [TBL] [Abstract][Full Text] [Related]
27. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074 [TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer]. Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668 [TBL] [Abstract][Full Text] [Related]
29. Alpha 1-antichymotrypsin-PSA (ACT-PSA): a useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate? Reiter W; Stieber P; Schmeller N; Nagel D; Fateh-Moghadam A Anticancer Res; 1997; 17(6D):4767-70. PubMed ID: 9494604 [TBL] [Abstract][Full Text] [Related]
30. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327 [TBL] [Abstract][Full Text] [Related]
31. Percent free PSA as an additional measure in a prostate cancer screen. Miele ME Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982 [TBL] [Abstract][Full Text] [Related]
32. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement. Bhuiyan AK; Kibria SA; Subhan SS Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483 [TBL] [Abstract][Full Text] [Related]
33. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484 [TBL] [Abstract][Full Text] [Related]
34. The variation of percent free prostate-specific antigen determined by two different assays. Yang CR; Ou YC; Horng YY; Lee HS Anticancer Res; 2003; 23(1B):707-11. PubMed ID: 12680171 [TBL] [Abstract][Full Text] [Related]
35. A higher PSA-density cut-off level in patients with intermediate PSA values for the early detection of prostate cancer. Mochtar CA; Rahardjo D; Umbas R Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():514-22. PubMed ID: 10895203 [TBL] [Abstract][Full Text] [Related]
36. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Nakamura T; Scorilas A; Stephan C; Jung K; Soosaipillai AR; Diamandis EP Cancer Res; 2003 Oct; 63(19):6543-6. PubMed ID: 14559849 [TBL] [Abstract][Full Text] [Related]
37. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer. Filella X; Alcover J; Corral JM; Molina R; Beardo P; Ballesta AM Anticancer Res; 2001; 21(5):3717-20. PubMed ID: 11848550 [TBL] [Abstract][Full Text] [Related]
38. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448 [TBL] [Abstract][Full Text] [Related]
39. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873 [TBL] [Abstract][Full Text] [Related]
40. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer]. Semjonow A; Hamm M; Rathert P Urologe A; 1993 May; 32(3):250-3. PubMed ID: 7685557 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]